|
Breast Carcinoma
|
0.600 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Malignant neoplasm of breast
|
0.560 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Neoplasm of uncertain or unknown behavior of breast
|
0.300 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Breast adenocarcinoma
|
0.300 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
(2) The human homolog of int-2, located on chromosome 11q13, is frequently amplified in human primary tumors and is comprised in an amplification unit encompassing the hst gene, which is often coamplified; the amplification at the 11q13 locus in breast carcinomas correlates with a poor outcome of the disease.
|
2677918 |
1989 |
|
Refractory anemias
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RA-treatment repressed endogenous but not exogenous FGF4 expression.
|
9715278 |
1998 |
|
Rheumatoid Arthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RA-treatment repressed endogenous but not exogenous FGF4 expression.
|
9715278 |
1998 |
|
Kaposi Sarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
FGF4 and INT2 oncogenes are amplified and expressed in Kaposi's sarcoma.
|
10786811 |
2000 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Fgf4, a member of the fibroblast growth factor family, is frequently amplified in a variety of human cancers, however, its expression in neoplastic tissues is rarely detectable.
|
11146552 |
2000 |
|
Chronic myocardial ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor 4 gene therapy for chronic ischemic heart disease.
|
18555186 |
2008 |
|
Neoplasm Metastasis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
HST-1 and INT-2 genes which is a member of fibroblast growth factor gene family, are amplified in approximately 50% of primary tumors and all the metastatic tumors of esophageal carcinomas.
|
2098274 |
1990 |
|
Carcinoma
|
0.060 |
AlteredExpression
|
group |
BEFREE |
HST-1 and INT-2 genes which is a member of fibroblast growth factor gene family, are amplified in approximately 50% of primary tumors and all the metastatic tumors of esophageal carcinomas.
|
2098274 |
1990 |
|
Germ Cell Cancer
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Hst-1/kFGF and bFGF are commonly expressed in five of seven male germ cell cancer lines.
|
2158037 |
1990 |
|
Pituitary Adenoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor 4 is implicated in PA pathogenesis; therefore, in this study, we used an isogenic mammosomatotroph cell line (GH4C1) harboring different fibroblast growth factor receptor (FGFR)-4 genotypes to establish and characterize intracranial xenograft mouse models that can be used for preclinical drug testing.
|
27267848 |
2016 |
|
Ewings sarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fgf-4 enhancer constructs showed that EWS-Oct-4 transactivated the Fgf-4 gene reporter in vitro, and that overexpression of EWS-Oct-4 stimulated endogenous Fgf-4 gene expression in vivo.
|
31155838 |
2019 |
|
Healing ulcer
|
0.010 |
Biomarker
|
disease |
BEFREE |
HST-1 reversed the adverse effects of IND on several inflammatory (myeloperoxidase, cytokines, adhesion molecules etc.) and ulcer-healing (cyclooxygenases, prostaglandin, growth factors and their receptors etc.) parameters in mice.
|
31215272 |
2019 |
|
Liver carcinoma
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
A comparative genomic hybridization analysis using one frozen HCC sample from a responder demonstrated that the 11q13 region, a rare amplicon in HCC including the loci for FGF3 and FGF4, was highly amplified.
|
22890726 |
2013 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
A growth inhibitory assay showed that only one FGF3/FGF4-amplified and three FGFR2-amplified cancer cell lines exhibited hypersensitivity to sorafenib in vitro.
|
22890726 |
2013 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
A growth inhibitory assay showed that only one FGF3/FGF4-amplified and three FGFR2-amplified cancer cell lines exhibited hypersensitivity to sorafenib in vitro.
|
22890726 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A significant association between tumor stage and hst-1 expression in the nonseminoma group was found (P = 0.0002, chi 2 test).
|
1706218 |
1991 |
|
testicular nonseminoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A significant association between tumor stage and hst-1 expression in the nonseminoma group was found (P = 0.0002, chi 2 test).
|
1706218 |
1991 |
|
Thrombocytopenia
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
A single Adex1HST-1 injection caused continuously increased levels of serum HST-1 protein for at least 30 d and increased the count of large megakaryocytes in bone marrow, which specifically recovered platelet counts and more efficiently diminished the extent and duration of thrombocytopenia than any other reported cytokine or any combination of cytokines so far.
|
7635948 |
1995 |
|
Germ Cell Cancer
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
A subset of male germ cell cancers presenting with advanced stage abundantly express the fibroblast growth factor-4 (FGF4).
|
9715278 |
1998 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
Biomarker
|
disease |
LHGDN |
Adherent stromal layers from 13 patients with AML and from six non-leukemic controls were established with 3ng/ml of FGF-4, EGF or TGF-beta1.
|
12163055 |
2002 |
|
Fibrosis, Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
ADSCs were engineered to overexpress miRNA-181-5p (miR-181-5p-ADSCs) to selectively home exosomes to mouse hepatic stellate (HST-T6) cells or a CCl4-induced liver fibrosis murine model and compared with non-targeting control Caenorhabditis elegans miR-67 (cel-miR-67)-ADSCs.
|
28382720 |
2017 |